Role of 18 FDG PET/CT in breast cancer. by Fatima, Nosheen & uz Zaman, Maseeh
eCommons@AKU
Department of Radiology Medical College, Pakistan
March 2018
Role of 18 FDG PET/CT in breast cancer.
Nosheen Fatima
Aga Khan University, nosheen.fatima@aku.edu
Maseeh uz Zaman
Aga Khan University, maseeh.uzzaman@aku.edu
Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_radiol
Part of the Radiology Commons
Recommended Citation
Fatima, N., uz Zaman, M. (2018). Role of 18 FDG PET/CT in breast cancer.. Journal of the College of Physicians and Surgeons Pakistan,
28(3), 177-179.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_radiol/108
Breast cancer (BC) is the most common female cancerworldwide. Despite a well-documented decline inmortality from BC over the past two decades, theincidence rate continues to rise more rapidly. Asia has agreater disease burden as compared with SouthAmerica and Africa.1 Unfortunately, Pakistan has thehighest incidence of BC and associated mortalities inAsia.2 Situation gets more perplexed due to diversebehaviours of BC in Pakistan like onset at younger age,and higher odds in multiparous and well-lactatingmothers, which contribute to documented high diseaseburden.2 Despite continuous efforts by governmentaland non-governmental organisations for enhancingawareness among females, diagnosis at an earlier stagehas been disappointing.3 Fifty-eight percent of Pakistaniwomen do have stage III disease at the time ofpresentation.4 Like other malignancies, early diagnosisand precise staging of BC can help in minimisingdisease-related mortality.
Diagnostic strategy includes breast self-examination,periodical mammogram, ultrasound or breast MRI inproblematic cases, guided biopsy in cases if a lump isidentified, contrast enhanced CT and bone scan for stagingbeyond T3N1 disease. Although 18-Flourodeoxyglucose(18FDG) positron emission tomogram with CT (PET/CT)is a proven powerful imaging tool with established role invarious malignancies, its role in BC is still evolving. Thiseditorial will highlight the utility and limitations of 18FDGPET/CT in BC.
Uptake of 18FDG on PET/CT indicates utilisation ofglucose by the tumor cells as energy source. However,the magnitude of 18FDG uptake depends upon certainbiological factors, which need to be known beforeaddressing the indications. Like all cancers, over-expression of glucose transporter GULT receptors,hexokinase enzymes and increased mitotic index arethe primary determinants of labelled glucose uptake.In addition, other biological factors having directassociation with glucose metabolism include histologicalgrading, proliferative index (ki67), p53 mutation, tumorcell burden, micro-vascularity, necrotic volume. Simliarly,
estrogen/progesterone/human epidermal growth receptors(ER/PR/HER-2, respectively) status also determines theradiotracer uptake (higher FDG uptake in triple negativeBC).5
Standardised uptake value (SUV) is the semi-quantitativemeasure indicating the intensity of uptake andmetabolism of 18FDG by tumor cells. In BC, the SUV hasan established role in therapy response evaluation andprognostication. SUV has the direct correlation withcomplete pathological response (pCR) after neo-adjuvant chemotherapy (NAC) in BC and indirectcorrelation with progression-free survival (PFS) andoverall survival (OS).
At present, various guidelines regarding management ofBC have been published by professional societies, butno unanimity is found about the role of 18FDG PET/CT.National Comprehensive Cancer Network (NCCN) in itsnarrative summary, published in February 2016,discourages the use of 18FDG in staging of patients withprimary operable and metastatic (stage IV) BC.6However, it favours the use of 18FDG in staging of locallyadvanced BC (LABC) and inflammatory BC (IBC).American Society of Clinical Oncology (ASCO)recommends 18FDG PET/CT for staging in patients withhigh clinical suspicion of metastasis and recurrence.Recently published appropriate use criteria (AUC) bySociety of Nuclear Medicine and Molecular Imaging(SNMMI),6 favour the role of 18FDG PET/CT in restagingand predicting response to therapy in BC. It is imperativefor reporting physicians and referring oncologists to becognizant of the justified indications of 18FDG PET/CTand also its limitations in different clinical scenarios. Thisstrategy would ensure the optimal utilisation of thissensitive tool for patients with BC.
So far there is no consensus about utility of 18FDGPET/CT in the diagnosis of BC due to the finiteresolution of PET scanners resulting in inability toidentify a tumor less than 2 cm (<pT1) and higher falsenegative rate in lobular carcinoma (about 65%) due tolow 18FDG avidity. Since early stage, BC (stage I and II)has a very low likelihood of distant metastasis; adding18FDG PET/CT to the diagnostic paradigm, could bemisleading due to false positive findings resulting inincorrectly upstaging or unjustified further investigations.7However, in challenging clinical scenarios like breastwith prosthesis or dense breast, 18FDG-based positronemission mammography (PEM) is considered to havebetter sensitivity, specificity, and diagnostic accuracydue to higher resolution than existing PET/CT scanner.8
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18FDG PET/CT can detect a malignant breast lesion inpatients undergoing 18FDG PET/CT for other reasons orvice versa.9
Precise staging is the mainstay for selecting correcttherapeutic strategy and ultimate prognosis in BC. InTNM (tumor, node, metastasis) staging, 18FDG PET/CTis complementary to conventional imaging (CI) inT staging due to its limited resolution, but superior to CIfor detecting extra-axillary nodal and distant metastasis.American Joint Committee on Cancer (AJCC) andNCCN guidelines recommend use of 18FDG PET/CT instaging for IBC and LABC (Stage IIIA excluding T3N1b,IIIB and IIIC), and do not favour its use in staging of BCearlier than stage III or known stage IV disease.10Interestingly, there is reported evidence of about 30%additional extra-axillary node and distant metastasisdetected by 18FDG PET/CT as compared with CI.11Ongoing studies are expected to change the existingrecommendations in near future.
Due to the limited sensitivity (around 37%) of 18FDGPET/CT for axillary lymph node (ALN) metastasis, thesentinel lymph node (SLN) mapping is still consideredstandard of care for ALN staging.12 However, a positive18FDG PET/CT for ALN uptake, obviates the need ofSLN mapping due to its higher positive predictive valueand specificity, which is about 96%.12 Similarly, 18FDGPET/CT compared with CI has better detection efficiencyfor internal mammary, supraclavicular and mediastinalgroups of lymph nodes and has a definite impact ontherapy decision. 18FDG PET/CT has higher sensitivityfor marrow, osteolytic and mixed bony metastases, buthas limited role for pure sclerotic bone and hyper-metabolic brain metastasis.13 Subcentimeter pulmonarynodules pose diagnostic challenge to 18FDG PET/CTdue to breathing artifacts and partial volume effect.13
Most of the guidelines strongly favour the use of 18FDGPET/CT in restaging the BC patients with high clinicalsuspicion of recurrence.6,10 18FDG PET/CT has beenreported for modification in therapy decision in 48-57%patients with recurrent BC by viable tumor from post-therapy fibrosis and detecting the loco-regional anddistant recurrence with high diagnostic accuracy.13
There is a general consensus that earlier and midtherapy 18FDG PET/CT is more efficient than end oftherapy (EoT) in predicting the NAC response in BCpatients. However, normalisation of 18FDG uptake andSUV in follow-up 18FDG PET/CT does not have a provensensitivity for pCR, as it cannot rule out microscopicdisease.14 But residual 18FDG uptake or measureableSUV is a good predictor of treatment failure. To include18FDG PET/CT in the management paradigm wouldenable oncologists to identify non-responder for timelytherapy modification, and would save cost and unwantedexposure to cytotoxic agents.15
Currently, evidence is not sufficient to support the role of18FDG PET/CT in predicting response to hormonaltherapy. Transient increase in 18FDG uptake within 2weeks after starting tamoxifen (metabolic flare) isconsideres as a predictor of response; PET responsecorrelated with PFS but not OS in ER positive and HER-2negative BC patients. A 20% fall in SUVmax frombaseline is considered as a strong predictor of pCR andcCR.15 However, larger prospective multicentric trialscan explore the validity of such important findings.
There is a growing evidence that the magnitude of SUVhas direct correlation with poor outcome in BC.13 So far,no validated cut-off value of SUV has been agreed uponfor predicting response, and evidence from several on-going clinical trials is awaited.
Use of 18FDG PET/CT is strongly discouraged by majorguidelines for surveillance of asymptomatic BC patientswho have already achieved complete response (pCRand cCR) to therapy. The primary reason is the non-specificity of 18FDG uptake; and possible false positiveresults could result in unjustified and futile investigations.
Role of 18FDG PET/CT in diagnostic and managementparadigm of BC has been evolving. Currently, it is notrecommended for diagnosis, staging of operable (stageI, II, and T3N1b) and stage IV disease, and axillary nodalinvolvement or surveillance in asymptomatic patients. Itis recommended in staging of IBC, LABC (IIIA-Cexcluding T3N1bM0), and in restaging of recurrent BC.18FDG PET/CT is also considered an emerging tool inprognostic stratification and assessing early response totherapy. Although most of the BC patients in Pakistanpresent as LABC, yet 18FDG PET/CT is significantlyunderutilised due to limited PET/CT facilities, high cost,and lack of multidisciplinary approach in the existingclinical environment.
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